title: Targeted therapy in HER2-positive breast cancer.
abstract: Treatment options for breast cancer vary based on tumor surface markers and clinical factors, including cytotoxic chemotherapy, hormonal therapy, biological therapy or a combination thereof. An important molecular determinant of therapy is the human epidermal growth factor receptor 2 (HER2) positivity of the tumor, which has been identified in 20-25% of breast cancers and is a prognostic marker of poor outcome. The advent of HER2-targeted therapies has significantly improved the survival of patients with HER2-positive breast cancer. This review focuses on current HER2-targeted therapeutic options for patients with HER2-positive breast cancer, including monoclonal antibodies and tyrosine kinase inhibitors (TKIs).
authors.affiliation: Department of Chemotherapy, Cancer Center, Qilu Hospital of Shandong University, Jinan, Shandong 250012, P.R. China.
authors.forename: Shu Guang
authors.initials: SG
authors.lastname: Li
authors.affiliation: Department of Chemotherapy, Cancer Center, Qilu Hospital of Shandong University, Jinan, Shandong 250012, P.R. China.
authors.forename: Li
authors.initials: L
authors.lastname: Li
keywords: breast cancer; human epidermal growth factor receptor 2; monoclonal antibodies; targeted therapy; tyrosine kinase inhibitors